Nexentis Subsidiary MitoCareX Completes Initial AI Drug Screening
Nexentis said its subsidiary MitoCareX completed an initial AI drug screening with Boltz.
Related stories
Kingsgate Consolidated Reports Quarterly Gold and Silver Sales
Kingsgate Consolidated reported gold sales of 17,339 ounces and silver sales of 211,081 ounces for the quarter.
M impact | EQUITY | Oct 30, 2026, 01:46 AM UTC
Kingsgate Consolidated Produces 14,802 Ounces of Gold and 187,925 Ounces of Silver
The company reported an all-in sustaining cost of US$1,547 per ounce and said the metals were sold in the quarter.
L impact | EQUITY | Oct 30, 2026, 01:46 AM UTC
China’s Xinyi Sheng Drops 15.1% as Q3 Net Profit Falls
Xinyi Sheng shares fell as much as 15.1% Friday morning after its third-quarter net profit declined nearly one-fifth quarter over quarter.
M impact | EQUITY | Oct 30, 2026, 01:45 AM UTC
Mastercard Shares Rise More Than 4% After Q3 Results Beat Expectations
Mastercard shares gained more than 4% at Thursday’s close, reached a 52-week high of $641.56 during regular trading and logged their best session since January.
M impact | EQUITY | Oct 30, 2026, 01:45 AM UTC
Hyundai Glovis Q3 Operating Profit Rises 8.1%
Hyundai Glovis reported an 8.1% year-on-year rise in third-quarter operating profit.
M impact | EQUITY | Oct 30, 2026, 01:45 AM UTC
InnoLight Hong Kong shares hit record low, fall as much as 7.6%
InnoLight’s Hong Kong shares opened 7.1% lower Friday and fell as much as 7.6% intraday, setting a record low as the market digested its results.
M impact | EQUITY | Oct 30, 2026, 01:42 AM UTC